MELISSA KONKEN: Open Payments
NPI 1902358443 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,416 in 205 payments from 14 companies in 2025. Trend: 2023 $2,913 · 2024 $2,957 · 2025 $3,416
Food & beverage: $3,416
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $485 |
| Alkermes, Inc. | 24 | $473 |
| E.R. Squibb & Sons, L.L.C. | 24 | $461 |
| Corium, LLC | 22 | $317 |
| Vanda Pharmaceuticals Inc. | 16 | $304 |
| Neurocrine BioSciences, Inc. | 24 | $290 |
| ABBVIE INC. | 25 | $268 |
| Teva Pharmaceuticals USA, Inc. | 14 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $240 |
| Janssen Pharmaceuticals, Inc | 1 | $115 |
Products named: REXULTI, COBENFY, ARISTADA, Azstarys, INGREZZA, VRAYLAR, CAPLYTA, FANAPT.
Industry payments across IA — which companies pay providers there.
